Skip to main content

XBIT

Stock
Health Care
Biotechnology

Performance overview

XBIT Price
Price Chart

Forward-looking statistics

Beta
1.23
Risk
78.06%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.

Company info

SectorHealth Care
IndustryBiotechnology
Employees96
Market cap$205.3M

Fundamentals

Enterprise value
Revenue
Revenue per employee
Profit margin
Debt to equity

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)
Dividend per share
Revenue per share
Avg trading volume (30 day)
Avg trading volume (10 day)
Put-call ratio

Macro factor sensitivity

Growth+3.3
Credit+1.1
Liquidity-1.9
Inflation+0.9
Commodities+1.7
Interest Rates-2.3

Valuation

Dividend yield0.00%
PEG Ratio
Price to sales
P/E Ratio24.08
Enterprise Value to Revenue
Price to book

Upcoming events

Next earnings dayNovember 9, 2022
Next dividend day
Ex. dividend day

News

What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?

Tuesday, XBiotech Inc XBIT announced data from its Phase 1/Phase 2, 1-BETTER Study for advanced pancreatic cancer.

Benzinga (June 18, 2024)
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma

Two microcap biotech stocks to consider for the science-challenged among us.

Zacks Investment Research (March 7, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free